158 related articles for article (PubMed ID: 33487560)
1. First clinical implementation of GammaTile permanent brain implants after FDA clearance.
Ferreira C; Sterling D; Reynolds M; Dusenbery K; Chen C; Alaei P
Brachytherapy; 2021; 20(3):673-685. PubMed ID: 33487560
[TBL] [Abstract][Full Text] [Related]
2. GammaTile: Comprehensive Review of a Novel Radioactive Intraoperative Seed-Loading Device for the Treatment of Brain Tumors.
Ekhator C; Nwankwo I; Rak E; Homayoonfar A; Fonkem E; Rak R
Cureus; 2022 Oct; 14(10):e29970. PubMed ID: 36225241
[TBL] [Abstract][Full Text] [Related]
3. GammaTile for Gliomas: A Single-Center Case Series.
Budnick HC; Richardson AM; Shiue K; Watson G; Ng SK; Le Y; Shah MV
Cureus; 2021 Nov; 13(11):e19390. PubMed ID: 34925992
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomy.
McClelland S; Gardner UG; Le Y; Ng SK; Shah MV; Watson GA
Brachytherapy; 2021; 20(6):1265-1268. PubMed ID: 34588144
[TBL] [Abstract][Full Text] [Related]
5. Supplement 2 for the 2004 update of the AAPM Task Group No. 43 Report: Joint recommendations by the AAPM and GEC-ESTRO.
Rivard MJ; Ballester F; Butler WM; DeWerd LA; Ibbott GS; Meigooni AS; Melhus CS; Mitch MG; Nath R; Papagiannis P
Med Phys; 2017 Sep; 44(9):e297-e338. PubMed ID: 28644913
[TBL] [Abstract][Full Text] [Related]
6. GammaTile
Gessler DJ; Ferreira C; Dusenbery K; Chen CC
Future Oncol; 2020 Oct; 16(30):2445-2455. PubMed ID: 32618209
[TBL] [Abstract][Full Text] [Related]
7. The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.
Garcia MA; Turner A; Brachman DG
J Neurooncol; 2024 Jan; 166(2):203-212. PubMed ID: 38261141
[TBL] [Abstract][Full Text] [Related]
8. Treating Recurrent Brain Metastases Using GammaTile Brachytherapy: A Case Report and Dosimetric Modeling Method.
Arsenault T; Labak CM; Chaung K; Muzic RF; Kardan A; Sloan A; Choi S; Podder T; Ouyang Z
Cureus; 2021 Nov; 13(11):e19232. PubMed ID: 34877209
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric Impact of Source Displacement in GammaTile Surgically Targeted Radiation Therapy for Gliomas.
Ng SK; Yue Y; Shiue K; Shah MV; Le Y
Cureus; 2023 May; 15(5):e38463. PubMed ID: 37273347
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group.
Bice WS; Prestidge BR; Kurtzman SM; Beriwal S; Moran BJ; Patel RR; Rivard MJ;
Brachytherapy; 2008; 7(4):290-6. PubMed ID: 18782682
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Commissioning and Clinical Implementation of GammaTiles STaRT for Intracranial Brain Cancer.
Penoncello GP; Gagneur JD; Vora SA; Yu NY; Fatyga M; Mrugala MM; Bendok BR; Rong Y
Adv Radiat Oncol; 2022; 7(4):100910. PubMed ID: 35434425
[TBL] [Abstract][Full Text] [Related]
12. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States.
Prete JJ; Prestidge BR; Bice WS; Friedland JL; Stock RG; Grimm PD
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):1001-5. PubMed ID: 9531387
[TBL] [Abstract][Full Text] [Related]
13. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
14. Cesium-131 permanent seed brachytherapy: dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff.
Parashar B; Wernicke AG; Pavese A; Singh P; Trichter S; Sabbas A; Kutler DI; Kuhel W; Port JL; Lee PC; Nori D; Chao KS
Brachytherapy; 2011; 10(6):508-13. PubMed ID: 21640663
[TBL] [Abstract][Full Text] [Related]
15. GammaTile Brachytherapy Combined With External Beam Radiation Therapy for the Treatment of a Partially Resected Secondary Glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching External Beam Dose Gradient to Brachytherapy Dose Fall-Off.
Peach MS; Burke AM; Jo J; Ju AW; Yang K
Cureus; 2021 Nov; 13(11):e19717. PubMed ID: 34934580
[TBL] [Abstract][Full Text] [Related]
16. First clinical implementation of Yttrium-90 Disc Brachytherapy after FDA clearance.
Finger PT; Stewart R; Rivard MJ; Beers RJ; Kamen J; Lama S; Chin KJ; Mohney K; Welles TS; Sauerwein WAG; Rosenzweig K
Brachytherapy; 2023; 22(3):416-427. PubMed ID: 36948988
[TBL] [Abstract][Full Text] [Related]
17. Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64.
Yu Y; Anderson LL; Li Z; Mellenberg DE; Nath R; Schell MC; Waterman FM; Wu A; Blasko JC
Med Phys; 1999 Oct; 26(10):2054-76. PubMed ID: 10535622
[TBL] [Abstract][Full Text] [Related]
18. The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer.
Bittner NH; Orio PF; Merrick GS; Prestidge BR; Hartford AC; Rosenthal SA
Brachytherapy; 2017; 16(1):59-67. PubMed ID: 28109632
[TBL] [Abstract][Full Text] [Related]
19. Outpatient template-guided permanent interstitial brachytherapy using
Feddock J; Aryal P; Steber C; Edwards J; Cheek D; Randall M
Brachytherapy; 2017; 16(2):393-401. PubMed ID: 28139423
[TBL] [Abstract][Full Text] [Related]
20. Interstitial brachytherapy dosimetry update.
Rivard MJ; Nath R
Radiat Prot Dosimetry; 2006; 120(1-4):64-9. PubMed ID: 16614084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
